HLX208
As of the edition of 20 October 2026, HLX208 is a drug known only by a code name: of no established status; acts on BRAF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 10, 0 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BRAF | Serine/threonine-protein kinase B-raf | P15056 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 8 | 0 | 0 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Henlius Biotech | Lead sponsor of trials | 2021 to now |